Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

18F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
Nedelská, Zuzana , Josephs, Keith A. , Graff‐Radford, Jonathan, Przybelski, Scott A. , Lesnick, Timothy G. , Drubach, Daniel A., Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer , Kantarci, Kejal , Jack, Clifford R , Nedelska, Zuzana , Kantarci, Kejal , Graff‐Radford, Jonathan , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Movement Disorders | January 8, 2019 | Volume: 34 | Issue: 3 | Pages: 344-352

10.1002/mds.27603 | PMID 30615804 Get It

AbstractBackgroundPosterior cortical atrophy and dementia with Lewy bodies are 2 distinct clinical syndromes, yet they can overlap in symptoms and occipital hypometabolism. Patients with dementia with Lewy bodies often have overlapping Alzheimer's disease pathology. Similarly, Lewy bodies can be found in patients with posterior cortical atrophy. We investigated differences in the distribution and magnitude of F18‐AV‐1451 uptake in patients with these 2 syndromes.MethodsConsecutive patients with probable dementia with Lewy bodies (n = 33), posterior cortical atrophy (n = 18), and cognitively unimpaired controls (n = 100) underwent 18F‐AV‐1451 positron emission tomography. Regional differences in AV‐1451 uptake were assessed using voxel‐wise and an atlas‐based approach. The greatest differences in AV‐1451 uptake between patient groups were identified using area under receiver operating curve statistics, and a composite region was derived.ResultsAV‐1451 uptake in both patient groups was predominantly localized to the lateral occipital regions, but the magnitude of uptake was markedly greater in posterior cortical atrophy compared with dementia with Lewy bodies. The posterior cortical atrophy group showed the greatest AV‐1451 uptake throughout all the gray matter compared with that in other groups. The occipital composite region, consisting of superior, middle, and inferior occipital cortices, distinguished posterior cortical atrophy from dementia with Lewy bodies (area under the curve >0.97; P < 0.001, Bonferroni‐corrected) with excellent sensitivity (88%) and specificity (100%).ConclusionsPosterior cortical atrophy and dementia with Lewy bodies can share clinical features, and although the pattern of AV‐1451 uptake in occipital cortices overlaps between these 2 syndromes, its magnitude is significantly higher in posterior cortical atrophy. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Reply by Authors
Jimbo, Masaya , Granberg, Candace F. , Osumah, Tijani , Bandari, Jathin , Cannon, Glenn M., Gargollo, Patricio C. , Routh, Jonathan C.

Mayo Clinic

Journal of Urology | January 8, 2019 | Volume: 201 | Issue: 2 | Pages: 398-399

10.1097/01.ju.0000552993.91520.99 | PMID 30634378 Get It

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert , Connors, Joseph M. , Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Gopal, Ajay K. , Younes, Anas , Engley, Gerald, Manley, Thomas, Fenton, Keenan , Straus, David J. , Gordon, Leo I , Connors, Joseph M , Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J.

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 6 | Pages: 1718-1726

10.1158/1078-0432.ccr-18-2435 | PMID 30617130 Get It

Abstract Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Results: The NA subgroup consisted of 497 subjects in the A+AVD (n = 250) and ABVD (n = 247) arms. Similar to the primary analysis based on the intent-to-treat population, the primary endpoint [modified progression-free survival (PFS) per independent review] demonstrated an improvement among subjects who received A+AVD compared with ABVD (HR = 0.60; P = 0.012). For PFS, the risk of progression or death was also reduced (HR = 0.50; P = 0.002). Subsequent anticancer therapies were lower in the A+AVD arm. Grade 3 or 4 adverse events (AEs) were more common, but there were fewer study discontinuations due to AEs in the A+AVD arm as compared with ABVD. Noted differences between arms included higher rates of febrile neutropenia (20% vs. 9%) and peripheral neuropathy (80% vs. 56%), but lower rates of pulmonary toxicity (3% vs. 10%) in subjects treated with A+AVD versus ABVD. Conclusions: The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST
Jones, Michael R. , Howard, George , Roubin, Gary S., Blackshear, Joseph L., Cutlip, Donald E. , Leimgruber, Pierre P., Prineas, Ronald J. , Lal, Brajesh K. , Voeks, Jenifer H. , Brott, Thomas G. , Investigators, for the CREST, Howard, George , Cohen, David Jonathan , Rhodes, David , Glasser, Stephen P. , Investigators, for the CREST

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 7, 2019 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/circoutcomes.117.004663 | PMID 30571337 Get It

Background: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) previously reported increased mortality in patients who sustained a periprocedural stroke or cardiac event (myocardial infarction [MI] or biomarker only) in follow-up to 4 years. We now extend these observations to 10 years. Methods and Results: CREST is a randomized controlled trial designed to compare the outcomes of carotid stenting versus carotid endarterectomy. Proportional hazards models were used to assess the association between mortality and periprocedural stroke, MI, or biomarker-only events. For 10-year follow-up, patients with periprocedural stroke were at 1.74× the risk of death compared with those without stroke (adjusted hazard ratio [HR]=1.74; 95% CI, 1.21–2.50; P <0.003). This increased risk was driven by increased early (between 0 and 90 days) mortality (adjusted HR=14.41; 95% CI, 5.33–38.94; P <0.0001), with no significant increase in late (between 91 days and 10 years) mortality (adjusted HR=1.40; 95% CI, 0.93–2.10; P =0.11). Patients with a protocol MI were at 3.61× increased risk of death compared with those without MI (adjusted HR=3.61; 95% CI, 2.28–5.73; P <0.0001), with an increased hazard both early (adjusted HR=8.20; 95% CI, 1.86–36.2; P =0.006) and late (adjusted HR=3.40; 95% CI, 2.09–5.53; P <0.0001). Patients with a biomarker-only event were at 2.04× increased risk overall (adjusted HR=2.04; 95% CI, 1.09–3.84; P =0.03) than those without MI, with an increased early hazard (adjusted HR=8.44; 95% CI, 1.09–65.5; P =0.04) and a suggestive but nonsignificant association toward higher 91-day to 10-year risk (1.88; 95% CI, 0.97–3.64; P =0.062) contributing to the increased risk. Conclusions: In the CREST trial, patients with periprocedural events demonstrate a substantial increase in future mortality to 10 years. For stroke, this risk is largely confined to an early time frame while periprocedural MI or biomarker-only events confer a continuous increased mortality for 10 years. Strategies to reduce periprocedural events and to optimize the evaluation and management of patients with cardiac events should be considered in efforts to reduce not only early but also long-term mortality. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00004732.
Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.
Trudel, Suzanne , White, Darrell , Sabry, Waleed , Belch, Andrew R. , Reiman, Tony , Shustik, Chaim, Kovacs, Michael J. , Sussman, Jonathan , Reece, Donna , Lacy, Martha Q. , Meyer, Ralph M., Shepherd, Lois E. , Whelan, Kate, Zhu, Liting , Chapman, Judy‐Anne W., Stewart, A. Keith, Hay, Annette E. , Bahlis, Nizar Jacques , Roy, Jean

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8591-8591

10.1200/jco.2014.32.15_suppl.8591 Get It

Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts).
Nabhan, Chadi , Byrtek, Michelle, Dawson, Keith, Friedberg, Jonathan W. , Flowers, Christopher R. , Zhou, Xiaolei , Ziemiecki, Ryan , Zelenetz, Andrew D. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8550-8550

10.1200/jco.2014.32.15_suppl.8550 Get It

Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
Rizvi, Naiyer A. , Patnaik, Amita , Balmanoukian, Ani Sarkis, Blumenschein, George R. , Gubens, Matthew A. , Papadopoulos, Kyriakos P. , Lubiniecki, Gregory M., Zhang, Jin , Niewood, Michelle, Emancipator, Kenneth , Dolled‐Filhart, Marisa, Hanson, Mary E. , Hui, Rina , Garon, Edward B. , Gandhi, Leena , Leighl, Natasha B , Goldman, Jonathan W. , Eder, Joseph P. , Johnson, Elizabeth Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8007-8007

10.1200/jco.2014.32.15_suppl.8007 Get It

The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience.
Bar‐Ad, Voichita , Axelrod, Rita , Rosenthal, D.I., Trotti, Andy, Jones, Christopher U. , Song, Guobin , Foote, Robert L. , Raben, David, Shenouda, George , Spencer, Sharon A., Zhang, Qiang , Harari, Paul M. , Garden, Adam S. , Harris, Jonathan , Le, Quynh‐Thu

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6025-6025

10.1200/jco.2014.32.15_suppl.6025 Get It

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.
McNeish, Iain A. , Allen, Andrew R., Raponi, Mitch , Giordano, Heidi, Maloney, Lara , Isaacson, Jeff, McNeish, Iain A , Swisher, Elizabeth M. , Coleman, Robert L. , Brenton, James D. , Kaufmann, Scott H. , Isaacson, Jeffrey D., Ledermann, Jonathan A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS5619-TPS5619

10.1200/jco.2014.32.15_suppl.tps5619 Get It